Jacobs A D, Champlin R E, Golde D W
Blood. 1985 Apr;65(4):1017-20.
Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) alpha-2-interferon in an open-label, single-arm efficacy study. Patients received 2 X 10(6) U/m2 recombinant alpha-2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of therapy with recombinant alpha-2-interferon indicates a significant improvement in hemoglobin, granulocyte, and platelet counts. Bone marrow biopsies in six of 14 patients after six months of therapy showed a greater than 50% decrease in the infiltration of leukemia cells. We conclude that recombinant alpha-2-interferon is highly effective therapy for hairy cell leukemia.
在一项开放标签、单臂疗效研究中，22例毛细胞白血病患者接受了生物合成（重组）α-2干扰素治疗。患者每周三次接受2×10⁶U/m²重组α-2干扰素治疗。治疗在主观上耐受性良好，短期血液学毒性极小。在研究期间，两名患者发生细菌感染，一名患者经历了角膜移植短暂的、易于逆转的排斥反应。对研究开始时和使用重组α-2干扰素治疗三至六个月后的平均血液学指标进行统计学比较，结果表明血红蛋白、粒细胞和血小板计数有显著改善。14例患者中有6例在治疗六个月后进行的骨髓活检显示白血病细胞浸润减少超过50%。我们得出结论，重组α-2干扰素是治疗毛细胞白血病的高效疗法。
